PEMF for Elderly Patients.

June 2026 · 9 min read · Clinical Protocol

The Geriatric Pain Problem: Why It's Different

Chronic pain in elderly patients presents a clinical challenge unlike any other patient cohort. In the Philippines, 40–60% of adults aged 65 and older live with some form of chronic pain — affecting an estimated 3.3 to 4.9 million Filipinos. Yet the pharmacological toolkit for managing this pain is severely constrained by age-related physiological changes and the reality of polypharmacy.

The average elderly Filipino patient takes five or more medications concurrently. Every additional drug introduces compounding risks: drug-drug interactions, organ toxicity accumulation, and cognitive burden. The very analgesics most commonly prescribed for pain carry disproportionate risks in the elderly:

• NSAIDs (ibuprofen, naproxen, celecoxib): elevated GI bleeding risk and nephrotoxicity in patients with declining renal function — a near-universal feature of aging
• Opioids (tramadol, codeine, morphine): increased fall risk, cognitive impairment, constipation, and respiratory depression at doses that younger patients tolerate normally
• Muscle relaxants and sedatives: contribute to falls, confusion, and daytime sedation — the leading causes of hospitalization and functional decline in the elderly
• Gabapentinoids: associated with cognitive blunting, dizziness, and gait instability in this population

The clinical result is a cohort with severe, often treatment-resistant pain — compounded by decades of disease progression — and no safe pharmacological escalation pathway. Geriatric pain medicine demands a fundamentally different approach: one that delivers meaningful pain relief without adding to the systemic burden. PEMF was not designed specifically for elderly patients, but it fits their needs almost perfectly.

Why PEMF Is Uniquely Suited for Elderly Patients

PEMF (Pulsed Electromagnetic Field therapy) works through non-pharmacological mechanisms — electromagnetic field induction at the cellular level — which means it has no systemic absorption, no hepatic metabolism, and no renal clearance. For elderly patients, this translates into a clinical profile with no parallels among pharmacological options:

• Zero drug interactions: PEMF does not affect the absorption, distribution, metabolism, or elimination of any concurrent medication. Patients on five, eight, or ten medications can use PEMF without adjustment
• No systemic side effects: no GI irritation, no renal load, no cognitive effects, no sedation, no fall risk attributable to the treatment itself
• Non-invasive, comfortable delivery: treatment is administered in a seated or supine position, requiring no physical exertion from the patient — appropriate for frail elderly individuals
• No supervision required during treatment: the patient lies or sits with the applicator in place for the session duration; clinic staff can attend to other patients, reducing labor cost
• Treats multiple conditions simultaneously: elderly patients typically have two to four concurrent pain diagnoses (OA + spondylosis + osteoporosis is a common triad). PEMF protocols can be adapted to address multiple anatomical targets in a single session
• Works together with existing medications: they continue exactly as prescribed. It reduces pain through cellular pathways distinct from NSAIDs, opioids, or gabapentinoids — enabling medication tapering rather than escalation
• Accessible outside specialist settings: elderly patients often have limited mobility and cannot travel to specialist clinics. PEMF requires no medical supervision during treatment and can be delivered in community clinics, rehabilitation centers, and barangay health stations

Top 5 Geriatric Pain Conditions PEMF Addresses

1. Osteoarthritis

Osteoarthritis is the single most prevalent chronic pain condition in the elderly population worldwide. A meta-analysis of 11 RCTs with 614 patients (PMC9110240) demonstrated that PEMF produces statistically significant improvements across all three primary OA outcome domains: pain SMD=0.71 (p=0.03), stiffness SMD=1.34 (p=0.003), and function SMD=1.52 (p=0.004). The confidence intervals are wide and the trial pool is small and heterogeneous, so this figure must be read alongside a 2026 meta-analysis (9 RCTs, n=457, PubMed 42075549) which found no significant VAS or total WOMAC improvement at one month, no improvement in objective functional measures, and a high overall risk of bias. Both are presented here, because presenting only one is bias.

2. Lumbar and Cervical Spondylosis

Age-related spinal degeneration — manifesting as lumbar or cervical spondylosis with associated chronic back and neck pain — is the second most common geriatric pain presentation. A multicenter RCT across five orthopedic clinics (PMC11914662, 120 enrolled / 91 analysed) covering joint pain, soft-tissue pain, OA, bursitis, strains and tears — not spondylosis specifically — reported 36% pain reduction in the PEMF group versus 10% in standard care (p<0.0001), along with a 55% reduction in analgesic medication use versus 12% in the control group (p<0.0001). This medication reduction outcome is particularly compelling in the geriatric context, where reducing NSAID exposure directly lowers GI bleed and renal injury risk.

3. Osteoporosis and Fracture Risk

Osteoporosis affects an estimated 30–40% of women over 65 in the Philippines. Beyond the pain of vertebral compression fractures, the disease creates a cycle of functional decline, reduced activity, and accelerating bone loss. An RCT of 95 patients over 12 weeks (PMC8637238) found that PEMF combined with exercise produced greater bone mineral density (BMD) improvement than exercise alone, with effects persisting at 6-month follow-up. For elderly patients in whom high-impact exercise is contraindicated, PEMF offers a non-loading option aimed at supporting bone density.

4. Rheumatoid Arthritis

RA in elderly patients presents with the same systemic inflammatory burden as in younger patients, compounded by cumulative DMARD exposure and comorbid conditions. A clinical study of 39 RA patients (PMC10971695) found that PEMF added to standard therapy produced significant improvements: VAS pain reduced by 2.2 points (p=0.0000), morning stiffness duration reduced by 23.2 minutes (p=0.001), HAQ functional status improved by 0.26 points (p=0.0166), and range of motion improved by 1.9 mm (p=0.0036). All outcomes reached statistical significance without any modification to existing pharmacological therapy.

5. Post-Fracture Recovery

Hip fractures in patients over 65 carry a one-year mortality rate of 20–30% and a permanent mobility impairment rate exceeding 50%. Accelerating fracture healing and reducing post-fracture pain directly impacts survival outcomes. A meta-analysis of 14 RCTs with 1,131 patients (PMID 32495506) found that PEMF produced a healing rate of 79.7% versus 64.3% in controls (RR=1.22, 95% CI 1.10–1.35), pain SMD=−0.49, and healing time SMD=−1.01. The trial pool explicitly included elderly patients. Earlier healing enables earlier mobilization — the single most important predictor of post-fracture survival in geriatric patients.

Evidence Table by Condition

Clinical Protocol for Elderly Patients

The geriatric PEMF protocol is structured in three stages, recognizing that elderly patients require a conservative initial assessment, an active treatment phase, and a long-term maintenance framework to sustain gains:

Stage 1: Assessment (Sessions 1–2)

• Position: Supine or high-backed seated position with support for all limbs
• Duration: 20 minutes per session
• Frequency: 2 sessions in the first week
• Goal: Establish baseline VAS, functional mobility, and medication inventory; identify primary pain targets; assess tolerance to PEMF at standard parameters; screen for contraindications (active pacemaker, active malignancy in treatment area)
• Parameters: Begin at lower intensity; standard frequency settings for the presenting condition

Stage 2: Active Treatment (Sessions 3–15)

• Position: Supine or seated; no physical exertion required
• Duration: 25–30 minutes per session (per anatomical target)
• Frequency: 3 sessions per week
• Series length: 13 sessions over approximately 5 weeks
• Goal: Achieve primary pain reduction target (30–40% VAS reduction by session 10); begin supervised medication tapering conversation with prescribing physician if pain adequately controlled; reassess functional mobility every 5 sessions
• Multi-condition approach: For patients with OA + spondylosis, alternate target sites across sessions or use split-session protocol where feasible

Stage 3: Maintenance (Session 16 onwards)

• Position: Patient preference; typically same as active treatment
• Duration: 20–25 minutes per session
• Frequency: 1–2 sessions per week, ongoing
• Series length: Indefinite; reviewed quarterly
• Goal: Sustain pain relief achieved in active phase; prevent functional decline; support ongoing medication management; monitor for new pain diagnoses requiring protocol adjustment
• Review triggers: Increase frequency to 3x/week during acute flares (RA, OA exacerbation) or post-fracture recovery periods

Polypharmacy Reduction: The Business Case

The most significant clinical and economic outcome from the multicenter RCT (PMC11914662) is the 55% reduction in analgesic medication use in the PEMF group versus 12% in the control group (p<0.0001). For elderly patients, this is not merely a convenience — it is a risk reduction intervention with quantifiable downstream benefits:

• Reduced GI bleed risk: NSAIDs cause gastrointestinal bleeding in 1–4% of long-term users annually; in elderly patients with compromised mucosal protection, this risk is significantly higher
• Reduced renal injury risk: NSAIDs reduce renal prostaglandin synthesis, impairing blood flow regulation — a critical risk in elderly patients whose glomerular filtration rate is already declining at approximately 1 mL/min/year after age 40
• Lower cognitive burden: Opioids, gabapentinoids, and muscle relaxants all carry documented cognitive side effects in the elderly; reducing their use directly lowers dementia risk and fall incidence
• Fewer drug interactions: Each medication removed from a five-drug regimen eliminates multiple potential interaction pairs, reducing overall pharmacological complexity

The pharmacoeconomic case is equally compelling in the Philippine context. NSAIDs taken daily cost approximately ₱50–₱200 per day, totaling ₱18,250–₱73,000 annually. A complete PEMF treatment course (15 active sessions at ₱1,000–₱2,500 per session) costs ₱15,000–₱37,500 in total — often less than six months of daily NSAID use. Maintenance sessions (1–2 per week at ₱1,000–₱2,500) add ₱52,000–₱260,000 annually, but this must be weighed against medication costs, GI complication hospitalizations (average ₱80,000–₱200,000 per admission), and renal failure management costs.

For clinic operators, the business case is straightforward: elderly patients are the highest-frequency, longest-retention segment in community healthcare. A patient achieving 55% medication reduction through PEMF is a patient who attributes their improved quality of life to your clinic — and continues maintenance sessions for years.

PEMF vs. Standard Geriatric Pain Management

Safety Profile for Elderly Patients

PEMF has no pharmacokinetic profile, so there are no dosing adjustments for renal impairment, hepatic insufficiency, or body weight. That is a real advantage in this population — but it is a pharmacokinetic property, not a demonstration of efficacy, and it does not mean the device is free of contraindications. Screening is mandatory before the first session:

• Any active implanted electronic device is an absolute contraindication: pacemakers, implantable cardioverter-defibrillators, CRT devices, neurostimulators and implanted drug pumps. Implant prevalence rises sharply with age, so this question belongs on the intake form, not in the treatment room. Any other cardiac condition is a decision for the treating physician, not for the clinic operating the device
• No renal or hepatic dosing adjustments: PEMF has no pharmacokinetic profile; there is no dose to adjust for organ function decline
• No cognitive effects: Unlike opioids, gabapentinoids, and muscle relaxants, PEMF produces no sedation, confusion, or memory impairment. Elderly patients with mild cognitive impairment can use PEMF safely
• Osteoporosis — read the trial carefully: the RCT usually cited here (PMC8637238 / PubMed 34900231) enrolled 95 men with a mean age of 51, not an elderly cohort, and the groups that improved most were the two that exercised; PEMF alone performed worst. It does not support PEMF as a substitute for loading. A meta-analysis in older adults with primary osteoporosis (8 trials, n=411, PubMed 35130160) found PEMF non-inferior to first-line agents on BMD, at moderate-to-very-low certainty
• Post-fracture: a bone-healing meta-analysis (PubMed 32495506, 14 RCTs, n=1,131) reported a higher union rate (79.7% vs 64.3%, RR 1.22, 95% CI 1.10–1.35). When to start is the treating surgeon’s call — no trial has established a start day, and we do not publish one
• No cognitive contraindications: Elderly patients with dementia, mild cognitive impairment, or post-stroke cognitive changes are not contraindicated — they simply require caregiver-assisted positioning and monitoring of comfort during sessions

Absolute contraindications are not limited to cardiac devices: any active implanted electronic device, active malignancy in the treatment field, active infection at the site, and pregnancy all rule the treatment out. A new fall, new confusion or rapid functional decline calls for urgent geriatric assessment, not for a course of sessions. Anything outside that list is a clinical judgement for the treating physician — this page does not clear individual patients.

Philippine Market Opportunity

The Philippines presents one of the most favorable demographic and clinical environments in Southeast Asia for geriatric PEMF services. With a total population of 115 million and a rapidly aging median age, the elderly segment is both large and underserved:

• 8.2 million Filipinos aged 65 and older — a figure growing at approximately 4% annually as the first generation of post-war baby boomers reaches retirement age
• OA prevalence of 30–40% among the elderly translates to 2.5–3.3 million OA patients aged 65+ — the primary target market for geriatric PEMF services
• 36 million Filipinos with chronic pain of any type, with the highest concentration in the 55–75 age bracket
• Severe under-service outside Metro Manila: specialist rheumatologists, pain medicine physicians, and physical rehabilitation centers are concentrated in NCR, Cebu, and Davao. Community clinics, rural health units, and provincial hospitals lack access to evidence-based pain management alternatives — creating a gap that PEMF is uniquely positioned to fill, given that it requires no specialist supervision during treatment

Pricing is set by each clinic against its own cost base; we do not publish a per-session tariff. The calculation that matters to an operator is monthly equipment cost divided by that clinic’s own average revenue per session. Elderly patients in maintenance programs generate 48–104 sessions per year, creating predictable recurring revenue without the client acquisition cost of new patient recruitment.

The clinical model is validated at scale: more than 70 Israeli clinics now use this technology. The expansion to the Philippines represents the first international deployment of this model beyond Israel, with the community clinic framework specifically designed to replicate the Israeli per-capita reach in a larger, demographically younger but rapidly aging market.

Frequently Asked Questions

Is PEMF safe for elderly patients with a pacemaker?

No. The presence of an active implanted cardiac device — including permanent pacemakers, implantable cardioverter-defibrillators (ICDs), and cardiac resynchronization therapy (CRT) devices — is an absolute contraindication to PEMF. The electromagnetic fields generated by clinical PEMF devices can interfere with device sensing and pacing functions. Patients with pacemakers must not receive PEMF. All other cardiac conditions in elderly patients — hypertension, coronary artery disease, atrial fibrillation managed medically, or heart failure without a device — are not contraindications.

Can elderly patients use PEMF for multiple conditions simultaneously?

Yes. PEMF protocols can be adapted to treat multiple anatomical targets in a single session or across alternating sessions. Elderly patients with the common triad of OA (knee or hip) + lumbar spondylosis + osteoporosis can receive systemic protocols that deliver benefit across multiple conditions simultaneously, supplemented by targeted local protocols for the primary pain generator. The lack of cumulative systemic burden means that treating multiple conditions with PEMF does not increase risk — unlike adding a second or third analgesic medication.

Does PEMF improve balance and fall prevention through pain reduction?

No trial has shown that PEMF prevents falls, and we do not claim it. A meta-analysis in older adults (8 trials, n=411, PubMed 35130160) found a statistically significant Berg Balance Scale gain of 0.91 points — but the minimum detectable change on that scale in older people is 4 to 7 points (PubMed 19363567), so the change is significant without being clinically meaningful. In the one randomized trial that counted falls (PubMed 22817664) the rate was similar in both arms at 30 days, and the authors call for phase III trials before any fall-related benefit is claimed. What has been measured: gait speed rose 20.1% versus 10.5% on sham immediately after a single session in that same trial, and knee extensor strength rose 72% versus 25% at six months in a 2026 double-blind RCT (PubMed 41588476) — which found no change in walk time, chair stands or WOMAC. PEMF sessions run together with a supervised exercise programme, which carries the strongest fall-prevention evidence.

Important context on these figures. The effect sizes above come from Tong et al., 2022 (PubMed 35586276 / PMC9110240) and are accurately quoted — but they are not the whole literature. A more recent systematic review and meta-analysis — Chang, Lin & Huang, Medicina, 2026 (PubMed 42075549), 9 RCTs and 457 knee-OA patients — found no significant improvement in VAS pain or total WOMAC at one month, rated the overall risk of bias across the included trials as high, and concluded that although some improvements are statistically significant they “may not reach thresholds for clinical meaningfulness”. Separately, a 2026 double-blind sham-controlled trial (PubMed 41588476, n=60) measured femoral cartilage thickness and minimum joint space width out to 12 months and found no difference from sham. PEMF relieves symptoms; it does not rebuild the joint. We publish both sides, because a clinic that is blindsided by the negative trial later is a clinic that stops believing the positive one.

What is the maintenance protocol for elderly patients with chronic pain?

After completing the active treatment phase (typically 10–15 sessions over 4–6 weeks), elderly patients transition to a maintenance schedule of 1–2 sessions per week. For stable chronic conditions (OA, spondylosis), a once-weekly 25-minute session targeting the primary pain site is typically sufficient to sustain the gains achieved during active treatment. For patients with inflammatory components (RA) or those who have undergone fracture recovery, twice-weekly sessions during the first 3 months of maintenance provide more durable benefit. The maintenance phase should be reviewed quarterly — frequency can be reduced if pain control is stable, or temporarily increased to 3x/week during acute flares or post-injury recovery. There is no clinical rationale for discontinuing maintenance PEMF entirely in elderly patients with chronic pain, as the conditions driving the pain are not self-resolving.